Sevabertinib Makes HER2 Testing Actionable in NSCLC

from TheBrief.Health · host TheBrief.Health

FDA granted accelerated approval to sevabertinib for advanced nonsquamous NSCLC with activating HER2 kinase-domain mutations, emphasizing accurate biomarker identification and FDA-authorized diagnostic testing for eligibility.

Episode metadata supplied by the publisher feed · Published Sep 16, 2026

Embed this episode

Attribution link and audio player

Ready to play

Sevabertinib Makes HER2 Testing Actionable in NSCLC

0:00 1:36

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of TheBrief.Health?

This episode is 1 minute long.

When was this TheBrief.Health episode published?

This episode was published on September 16, 2026.

Can I download this TheBrief.Health episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!